ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Clinical Trials Study |
Article Title |
First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Chih-Ming Liang, Ming-Te Kuo, Ping-I Hsu, Chao-Hung Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Hsin-Ming Wang, Chih-Chien Yao, Cheng-En Tsai, Yao-Kuang Wang, Jiunn-Wei Wang, Chih-Fang Huang, Deng-Chyang Wu and Seng-Kee Chuah |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Research Foundation of Chang Gung Memorial Hospital (CMRPG8D1441), Taiwan |
|
|
Corresponding Author |
Seng-Kee Chuah, MD, Chief Doctor, Professor, Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao-Sung District, Kaohsiung 833, Taiwan. chuahsk@cmgh.org.tw |
Key Words |
Dexlansoprazole; Esomeprazole; One-week response; Complete symptom resolution rate; Gastroesophageal reflux disease |
Core Tip |
No existing report has investigated the short-term clinical effects of dexlansoprazole 60 mg vs esomeprazole 40 mg. This study compared the one-week clinical effects of a single dose of the two drugs for grades A and B erosive esophagitis. We enrolled 175 adult patients with gastroesophageal reflux disease (GERD) and randomized them in a 1:1 ratio into a dexlansoprazole (n = 88) or esomeprazole group (n = 87) for an intention-to-treat analysis (ITT). The primary end-points were the complete symptom resolution (CSR) rates at days 1, 3, and 7. The CSRs for both groups were similar at days 1, 3 and 7. In the subgroup analysis, female patients achieved higher CSRs in the dexlansoprazole group than in the esomeprazole group at day 3 (38.3% vs 18.4%, p = 0.046). In the esomeprazole group, female sex was a negative predictive factor for CSR at post-dose day 1 [OR = -1.249 ± 0.543; 95%CI: 0.287 (0.099-0.832), p = 0.022] and day 3 [OR = -1.254 ± 0.519; 95%CI: 0.285 (0.103-0.789), p = 0.016]. This pilot study suggested that the overall CSR rates for GERD patients were similar at days 1 through 7 for both the dexlansoprazole and esomeprazole groups, although a higher CSR was observed at day 3 in female patients who received a single dose of dexlansoprazole. |
Publish Date |
2017-12-20 02:49 |
Citation |
Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol 2017; 23(47): 8395-8404 |
URL |
http://www.wjgnet.com/1007-9327/full/v23/i47/8395.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v23.i47.8395 |